Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer

Free Radical Biology and Medicine

Volumn 102, Issue , 2017, Pages 122-132

  Fletcher, Nicole M ^a   Belotte, Jimmy ^a   Saed, Mohammed G ^a   Memaj, Ira ^a,b,c   Diamond, Michael P ^b   Morris, Robert T ^c   Saed, Ghassan M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Ovarian cancer; Oxidative stress; Single nucleotide polymorphism

Indexed keywords

BETA ACTIN; CATALASE; CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; DOCETAXEL; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE REDUCTASE; INDUCIBLE NITRIC OXIDE SYNTHASE; IRON SUPEROXIDE DISMUTASE; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRATE; NITRITE; OXIDOREDUCTASE; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; CRISPR CAS SYSTEM; ELECTRODERMAL RESPONSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IC50; OVARY CARCINOMA; OXIDATIVE STRESS; POINT MUTATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; GENOTYPE; NEOPLASM; OVARY TUMOR; OXIDATION REDUCTION REACTION; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 85002249060     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.11.028     Document Type: Article

References (67)

1. [1] Erickson, B.K., Conner, M.G., Landen, C.N. Jr., The role of the fallopian tube in the origin of ovarian cancer. Am. J. Obstet. Gynecol. 209:5 (2013), 409–414.
2. [2] Kajiyama, H., Shibata, K., Mizuno, M., Umezu, T., Suzuki, S., Sekiya, R., Niimi, K., Mitsui, H., Yamamoto, E., Kawai, M., Nagasaka, T., Kikkawa, F., Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology. J. Gynecol. Oncol. 25:1 (2014), 43–50.
3. [3] Lee, C., Macgregor, P., Drug resistance and microarrays. Mod. Drug Discov., 7, 2004, 7.
4. [4] Prat, J., Ribe, A., Gallardo, A., Hereditary ovarian cancer. Hum. Pathol. 36:8 (2005), 861–870.
5. [5] Ramus, S.J., Vierkant, R.A., Johnatty, S.E., Pike, M.C., Van Den Berg, D.J., Wu, A.H., Pearce, C.L., Menon, U., Gentry-Maharaj, A., Gayther, S.A., Dicioccio, R.A., McGuire, V., Whittemore, A.S., Song, H., Easton, D.F., Pharoah, P.D., Garcia-Closas, M., Chanock, S., Lissowska, J., Brinton, L., Terry, K.L., Cramer, D.W., Tworoger, S.S., Hankinson, S.E., Berchuck, A., Moorman, P.G., Schildkraut, J.M., Cunningham, J.M., Liebow, M., Kjaer, S.K., Hogdall, E., Hogdall, C., Blaakaer, J., Ness, R.B., Moysich, K.B., Edwards, R.P., Carney, M.E., Lurie, G., Goodman, M.T., Wang-Gohrke, S., Kropp, S., Chang-Claude, J., Webb, P.M., Chen, X., Beesley, J., Chenevix-Trench, G., Goode, E.L., Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J. Cancer 123:2 (2008), 380–388.
6. [6] Teraoka, S.N., Bernstein, J.L., Reiner, A.S., Haile, R.W., Bernstein, L., Lynch, C.F., Malone, K.E., Stovall, M., Capanu, M., Liang, X., Smith, S.A., Mychaleckyj, J., Hou, X., Mellemkjaer, L., Boice, J.D. Jr., Siniard, A., Duggan, D., Thomas, D.C., Concannon, P., Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Res., 13(6), 2011, R114.
7. [7] Sellers, T.A., Huang, Y., Cunningham, J., Goode, E.L., Sutphen, R., Vierkant, R.A., Kelemen, L.E., Fredericksen, Z.S., Liebow, M., Pankratz, V.S., Hartmann, L.C., Myer, J., Iversen, E.S. Jr., Schildkraut, J.M., Phelan, C., Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol. Biomark. Prev. 17:2 (2008), 397–404.
8. [8] Savas, S., Ozcelik, H., Phosphorylation states of cell cycle and DNA repair proteins can be altered by the nsSNPs. BMC Cancer, 5, 2005, 107.
9. [9] Kim, J.W., Dang, C.V., Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66:18 (2006), 8927–8930.
10. [10] Najafov, A., Alessi, D.R., Uncoupling the Warburg effect from cancer. Proc. Natl. Acad. Sci. USA 107:45 (2010), 19135–19136.
11. [11] Birben, E., Sahiner, U.M., Sackesen, C., Erzurum, S., Kalayci, O., Oxidative stress and antioxidant defense. World Allergy Organ J. 5:1 (2012), 9–19.
12. [12] Belotte, J., Fletcher, N.M., Awonuga, A.O., Alexis, M., Abu-Soud, H.M., Saed, M.G., Diamond, M.P., Saed, G.M., The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer. Reprod. Sci. 21:4 (2014), 503–508.
13. [13] Jiang, Z., Fletcher, N.M., Ali-Fehmi, R., Diamond, M.P., Abu-Soud, H.M., Munkarah, A.R., Saed, G.M., Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. Gynecol. Oncol. 122:2 (2011), 418–423.
14. [14] Reuter, S., Gupta, S.C., Chaturvedi, M.M., Aggarwal, B.B., Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 49:11 (2010), 1603–1616.
15. [15] Klaunig, J.E., Wang, Z., Pu, X., Zhou, S., Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol. Appl. Pharmacol. 254:2 (2011), 86–99.
16. [16] Brigelius-Flohe, R., Kipp, A., Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys. Acta 1790:11 (2009), 1555–1568.
17. [17] Sun, Y., Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic. Biol. Med. 8:6 (1990), 583–599.
18. [18] Buser, K., Joncourt, F., Altermatt, H.J., Bacchi, M., Oberli, A., Cerny, T., Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann. Oncol. 8:4 (1997), 335–341.
19. [19] Saydam, N., Kirb, A., Demir, O., Hazan, E., Oto, O., Saydam, O., Guner, G., Determination of glutathione, glutathione reductase, glutathione peroxidase and glutathione S-transferase levels in human lung cancer tissues. Cancer Lett. 119:1 (1997), 13–19.
20. [20] Singh, S.V., Brunnert, S.R., Roberts, B., Krishan, A., Differential expression of glutathione S-transferase, glutathione peroxidase and glutathione reductase in normal and malignant human breast tissues. Cancer Lett. 51:1 (1990), 43–48.
21. [21] Di Ilio, C., Sacchetta, P., Angelucci, S., Zezza, A., Tenaglia, R., Aceto, A., Glutathione peroxidase and glutathione reductase activities in cancerous and non-cancerous human kidney tissues. Cancer Lett. 91:1 (1995), 19–23.
22. [22] Popov, B., Gadjeva, V., Valkanov, P., Popova, S., Tolekova, A., Lipid peroxidation, superoxide dismutase and catalase activities in brain tumor tissues. Arch. Physiol. Biochem. 111:5 (2003), 455–459.
23. [23] Ray, G., Batra, S., Shukla, N.K., Deo, S., Raina, V., Ashok, S., Husain, S.A., Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res. Treat. 59:2 (2000), 163–170.
24. [24] Chung-man, Ho, J., Zheng, S., Comhair, S.A., Farver, C., Erzurum, S.C., Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res. 61:23 (2001), 8578–8585.
25. [25] Radenkovic, S., Milosevic, Z., Konjevic, G., Karadzic, K., Rovcanin, B., Buta, M., Gopcevic, K., Jurisic, V., Lactate dehydrogenase, catalase, and superoxide dismutase in tumor tissue of breast cancer patients in respect to mammographic findings. Cell Biochem. Biophys. 66:2 (2013), 287–295.
26. [26] Didziapetriene, J., Bublevic, J., Smailyte, G., Kazbariene, B., Stukas, R., Significance of blood serum catalase activity and malondialdehyde level for survival prognosis of ovarian cancer patients. Medicina 50:4 (2014), 204–208.
27. [27] Belotte, J., Fletcher, N.M., Saed, M.G., Abusamaan, M.S., Dyson, G., Diamond, M.P., Saed, G.M., A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival. PLoS One, 10(8), 2015, e0135739.
28. [28] Svensk, A.M., Soini, Y., Paakko, P., Hiravikoski, P., Kinnula, V.L., Differential expression of superoxide dismutases in lung cancer. Am. J. Clin. Pathol. 122:3 (2004), 395–404.
29. [29] Hu, Y., Rosen, D.G., Zhou, Y., Feng, L., Yang, G., Liu, J., Huang, P., Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J. Biol. Chem. 280:47 (2005), 39485–39492.
30. [30] Malone, J.M., Saed, G.M., Diamond, M.P., Sokol, R.J., Munkarah, A.R., The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer. Am. J. Obstet. Gynecol. 194:4 (2006), 1110–1116 (discussion 1116-8).
31. [31] Saed, G.M., Fletcher, N.M., Jiang, Z.L., Abu-Soud, H.M., Diamond, M.P., Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress. Reprod. Sci. 18:12 (2011), 1253–1261.
32. [32] Fletcher, N.M., Jiang, Z., Ali-Fehmi, R., Levin, N.K., Belotte, J., Tainsky, M.A., Diamond, M.P., Abu-Soud, H.M., Saed, G.M., Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer. Cancer Biomark 10:6 (2011), 267–275.
33. [33] Saed, G.M., Ali-Fehmi, R., Jiang, Z.L., Fletcher, N.M., Diamond, M.P., Abu-Soud, H.M., Munkarah, A.R., Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol. Oncol. 116:2 (2010), 276–281.
34. [34] Castillo-Tong, D.C., Pils, D., Heinze, G., Braicu, I., Sehouli, J., Reinthaller, A., Schuster, E., Wolf, A., Watrowski, R., Maki, R.A., Zeillinger, R., Reynolds, W.F., Association of myeloperoxidase with ovarian cancer. Tumour Biol. 35:1 (2014), 141–148.
35. [35] Lechner, M., Lirk, P., Rieder, J., Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin. Cancer Biol. 15:4 (2005), 277–289.
36. [36] Roy, K., Wu, Y., Meitzler, J.L., Juhasz, A., Liu, H., Jiang, G., Lu, J., Antony, S., Doroshow, J.H., NADPH oxidases and cancer. Clin. Sci. 128:12 (2015), 863–875.
37. [37] J. Belotte, N.M.Fletcher, A.O.Awonuga, M.Alexis, H.M.Abu-Soud, M.G.Saed, M.P.Diamond, G.M.Saed, The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer. Reprod. Sci., 2013.
38. [38] Lamendola, D.E., Duan, Z., Yusuf, R.Z., Seiden, M.V., Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res. 63:9 (2003), 2200–2205.
39. [39] Godwin, A.K., Meister, A., O'Dwyer, P.J., Huang, C.S., Hamilton, T.C., Anderson, M.E., High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89:7 (1992), 3070–3074.
40. [40] Zhao, P., Zhang, Z., Ke, H., Yue, Y., Xue, D., Oligonucleotide-based targeted gene editing in C. elegans via the CRISPR/Cas9 system. Cell Res. 24:2 (2014), 247–250.
41. [41] Fanning, J., Biddle, W.C., Goldrosen, M., Crickard, K., Crickard, U., Piver, M.S., Foon, K.A., Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. Gynecol. Oncol. 39:2 (1990), 119–122.
42. [42] Mahalingam, D., Medina, E.C., Esquivel, J.A. 2nd, Espitia, C.M., Smith, S., Oberheu, K., Swords, R., Kelly, K.R., Mita, M.M., Mita, A.C., Carew, J.S., Giles, F.J., Nawrocki, S.T., Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16:1 (2010), 141–153.
43. [43] Song, H.P., Wu, S.Q., Hao, H., Chen, J., Lu, J., Xu, X., Li, P., Yang, H., A chemical family-based strategy for uncovering hidden bioactive molecules and multicomponent interactions in herbal medicines. Sci. Rep., 6, 2016, 23840.
44. [44] C.L. Pearce, M.A.Rossing, A.W.Lee, R.B.Ness, P.M.Webb, G.Chenevix-Trench, S.J.Jordan, D.A.Stram, J.Chang-Claude, R.Hein, S.Nickels, G.Lurie, P.J.Thompson, M.E.Carney, M.T.Goodman, K.B.Moysich, E.V.Hogdall, A.Jensen, E.L.Goode, B.L.Fridley, J.M.Cunningham, R.A.Vierkant, R.P.Weber, A.Ziogas, H.Anton-Culver, S.A.Gayther, A.Gentry-Maharaj, U.Menon, S.J.Ramus, L.A.Brinton, N.Wentzensen, J.Lissowska, M.Garcia-Closas, L.Massuger, L.A.Kiemeney, A.M.van Altena, K.K.Aben, A.Berchuck, J.A.Doherty, E.Iversen, V.McGuire, P.G.Moorman, P.D.Pharoah, M.C.Pike, H.A.Risch, W.Sieh, D.O.Stram, K.L.Terry, A.S.Whittemore, A.Wu, J.M.Schildkraut, S.K.Kjaer, Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2013.
45. [45] Quick, S.K., Shields, P.G., Nie, J., Platek, M.E., McCann, S.E., Hutson, A.D., Trevisan, M., Vito, D., Modali, R., Lehman, T.A., Seddon, M., Edge, S.B., Marian, C., Muti, P., Freudenheim, J.L., Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol. Biomark. Prev. 17:5 (2008), 1082–1087.
46. [46] Forsberg, L., Lyrenas, L., de Faire, U., Morgenstern, R., A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic. Biol. Med. 30:5 (2001), 500–505.
47. [47] Yuzhalin, A.E., Kutikhin, A.G., Inherited variations in the SOD and GPX gene families and cancer risk. Free Radic. Res. 46:5 (2012), 581–599.
48. [48] Hileman, E.O., Liu, J., Albitar, M., Keating, M.J., Huang, P., Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother. Pharmacol. 53:3 (2004), 209–219.
49. [49] Geybels, M.S., Hutter, C.M., Kwon, E.M., Ostrander, E.A., Fu, R., Feng, Z., Stanford, J.L., Peters, U., Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate 73:7 (2013), 734–742.
50. [50] Jurkovic, S., Osredkar, J., Marc, J., Molecular impact of glutathione peroxidase in antioxidant processes. J. Croat. Soc. Med. Biochem. Lab. Med. 18:2 (2008), 162–174.
51. [51] Udler, M., Maia, A.T., Cebrian, A., Brown, C., Greenberg, D., Shah, M., Caldas, C., Dunning, A., Easton, D., Ponder, B., Pharoah, P., Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J. Clin. Oncol. 25:21 (2007), 3015–3023.
52. [52] Izakovicova Holla, L., Kankova, K., Znojil, V., Haplotype analysis of the NADPH oxidase p22 phox gene in patients with bronchial asthma. Int Arch. Allergy Immunol. 148:1 (2009), 73–80.
53. [53] Hodgkinson, A.D., Millward, B.A., Demaine, A.G., Association of the p22phox component of NAD(P)H oxidase with susceptibility to diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 26:11 (2003), 3111–3115.
54. [54] Macias-Reyes, A., Rodriguez-Esparragon, F., Caballero-Hidalgo, A., Hernandez-Trujillo, Y., Medina, A., Rodriguez-Perez, J.C., Insight into the role of CYBA A640G and C242T gene variants and coronary heart disease risk. A case-control study. Free Radic. Res. 42:1 (2008), 82–92.
55. [55] Miller, A.A., Drummond, G.R., Sobey, C.G., Selective inhibition of NADPH-oxidase isoforms as a therapeutic strategy in hypertension. Drug Discov. Today: Ther. Strateg. 2:3 (2005), 187–192.
56. [56] Zalba, G., San Jose, G., Beaumont, F.J., Fortuno, M.A., Fortuno, A., Diez, J., Polymorphisms and promoter overactivity of the p22(phox) gene in vascular smooth muscle cells from spontaneously hypertensive rats. Circ. Res. 88:2 (2001), 217–222.
57. [57] Shimo-Nakanishi, Y., Hasebe, T., Suzuki, A., Mochizuki, H., Nomiyama, T., Tanaka, Y., Nagaoka, I., Mizuno, Y., Urabe, T., Functional effects of NAD(P)H oxidase p22(phox) C242T mutation in human leukocytes and association with thrombotic cerebral infarction. Atherosclerosis 175:1 (2004), 109–115.
58. [58] Schirmer, M., Hoffmann, M., Kaya, E., Tzvetkov, M., Brockmoller, J., Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. Pharmacogenom. J. 8:4 (2008), 297–304.
59. [59] Wang, S.S., Davis, S., Cerhan, J.R., Hartge, P., Severson, R.K., Cozen, W., Lan, Q., Welch, R., Chanock, S.J., Rothman, N., Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis 27:9 (2006), 1828–1834.
60. [60] Vannini, F., Kashfi, K., Nath, N., The dual role of iNOS in cancer. Redox Biol. 6 (2015), 334–343.
61. [61] Jin, Z., Wang, W., Jiang, N., Zhang, L., Li, Y., Xu, X., Cai, S., Wei, L., Liu, X., Chen, G., Zhou, Y., Liu, C., Li, Z., Jin, F., Chen, B., Clinical implications of iNOS levels in triple-negative breast cancer responding to neoadjuvant chemotherapy. PLoS One, 10(7), 2015, e0130286.
62. [62] Tang, C.H., Grimm, E.A., Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J. Biol. Chem. 279:1 (2004), 288–298.
63. [63] Landriscina, M., Maddalena, F., Laudiero, G., Esposito, F., Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid. Redox Signal. 11:11 (2009), 2701–2716.
64. [64] Nussbaum, R.L., McInnes, R.R., Willard, H.F., Thompson, M.W., Hamosh, A., ScienceDirect (Online service), Thompson & Thompson Genetics in Medicine. 2007, Saunders/Elsevier, Philadelphia, 585.
65. [65] Sanchez, M., Torres, J.V., Tormos, C., Iradi, A., Muniz, P., Espinosa, O., Salvador, A., Rodriguez-Delgado, J., Fandos, M., Saez, G.T., Impairment of antioxidant enzymes, lipid peroxidation and 8-oxo-2′-deoxyguanosine in advanced epithelial ovarian carcinoma of a Spanish community. Cancer Lett. 233:1 (2006), 28–35.
66. [66] Alvero, A.B., Chen, R., Fu, H.H., Montagna, M., Schwartz, P.E., Rutherford, T., Silasi, D.A., Steffensen, K.D., Waldstrom, M., Visintin, I., Mor, G., Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8:1 (2009), 158–166.
67. [67] Chen, J., Wang, J., Chen, D., Yang, J., Yang, C., Zhang, Y., Zhang, H., Dou, J., Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol., 14, 2013, 7.